ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Chung, Carmen [1 ]
Jiang, Haiyan [2 ]
Isaranuwatchai, Wanrudee
Di Maio, Mas-Simo [3 ]
Lau, Anthea [2 ]
Hoch, Jeffrey
Feld, Ronald [2 ]
Tsao, Ming-Sound [4 ]
Gridelli, Cesare [5 ]
Gallo, Ciro [6 ]
Ciardiello, Fortunato [6 ]
Butts, Charles A. [7 ]
Perrone, Francesco [3 ]
Leighl, Natasha B. [8 ]
机构：
[1] Univ Toronto, Toronto, ON M5S 1A1, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Natl Canc Inst, Milan, Italy
[4] Princess Margaret Hosp, Toronto, ON, Canada
[5] Sg Moscati Hosp, Avellino, Italy
[6] Univ Naples 2, Naples, Italy
[7] Cross Canc Inst, Edmonton, AB, Canada
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cisplatin and gemcitabine; erlotinib; advanced non-small cell lung cancer; economic analysis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-020
引用
收藏
页码：S602 / S603
页数：2
相关论文
共 50 条
  • [31] A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer
    Blackhall, Fiona H.
    O'Brien, Mary
    Schmid, Peter
    Nicolson, Marianne
    Taylor, Paul
    Milenkova, Tsveta
    Kennedy, Sarah J.
    Thatcher, Nick
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1285 - 1288
  • [32] Gemcitabine and cisplatin as a first line therapy in non-small cell lung cancer: Preliminary Czech experience
    Pesek, M
    Eliasova, B
    Certikova, G
    ANNALS OF ONCOLOGY, 1998, 9 : 96 - 97
  • [33] GEMCITABINE-DOCETAXEL VERSUS CISPLATIN-GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER
    Al-Gizawy, S. M.
    Mostafa, H. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E15 - E15
  • [34] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [35] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [36] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
  • [37] COST EFFECTIVENESS OF ERLOTINIB VERSUS GEMCITABINE/CARBOPLATIN IN FIRST-LINE THERAPY OF ADVANCED EGFR-MUTATIONS POSITIVE NON-SMALL-CELL LUNG CANCER
    Hoang, B.
    Nguyen, T.
    VALUE IN HEALTH, 2016, 19 (03) : A152 - A152
  • [38] First-line treatment of advanced non-small-cell lung cancer (NSCLC) with vinorelbine and cisplatin.
    Bobilev, D
    Ariad, S
    Geffen, DB
    Cohen, Y
    ANNALS OF ONCOLOGY, 2000, 11 : 118 - 118
  • [39] ACTIVITY AND TOLERABILITY OF CARBOPLATIN AND GEMCITABINE IN FIRST-LINE TREATMENT OF ELDERLY THAI PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Charoentum, Chaiyut
    Theerakittikul, Theerakorn
    Saeteng, Somcharone
    Euathrongchit, Juntima
    Lertprasertsuke, Nirush
    Ariyawutyakorn, Witthawat
    Chewaskulyong, Busyamas
    Thongprasert, Sumitra
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1313 - S1313
  • [40] Docetaxel in combination with Gemcitabine as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Barata, Fernando
    Sousa, Amelia
    Camacho, Elvira
    Costa, Marco S.
    Canario, Dolores
    Nogueira, Fernando
    Semedo, Eulalia
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
12345